Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/96854
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Silva, Soraia | - |
dc.contributor.author | Bicker, Joana | - |
dc.contributor.author | Fonseca, Carla | - |
dc.contributor.author | Ferreira, Nuno R. | - |
dc.contributor.author | Vitorino, Carla | - |
dc.contributor.author | Alves, Gilberto | - |
dc.contributor.author | Falcão, Amílcar | - |
dc.contributor.author | Fortuna, Ana | - |
dc.date.accessioned | 2021-12-28T16:50:21Z | - |
dc.date.available | 2021-12-28T16:50:21Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1663-9812 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/96854 | - |
dc.description.abstract | Depression is a common mental disorder. Its treatment with selective serotonin reuptake inhibitors (SSRIs) is effective only in a fraction of patients, and pharmacoresistance is increasing steadily. Intranasal (IN) drug delivery to the brain stands out as a promising strategy to improve current therapeutic approaches by operating as a shuttle to overcome the blood-brain barrier. This work aimed to simultaneously administer escitalopram and paroxetine by IN route to mice. For this purpose, three nanostructured lipid carriers (NLC1, NLC2, and BorNLC) and one nanoemulsion (NE) were tested for drug loading. After their characterization, investigation of their impact on nasal cell viability and SSRI permeability assays were performed, using a human nasal RPMI 2650 cell line in air-liquid interface. In vitro assays demonstrated that NLCs, including borneol (BorNLC), significantly increased escitalopram permeability (p < 0.01) and paroxetine recovery values (p < 0.05) in relation to the other formulations and non-encapsulated drugs. IN and intravenous (IV) pharmacokinetic studies performed in vivo with a single dose of 2.38 mg/kg demonstrated similar results for escitalopram brain-to-plasma ratios. IN administrations delayed escitalopram peak concentrations in the brain for 15-60 min and no direct nose-to-brain delivery was detected. However, encapsulation with BorNLC considerably decreased escitalopram exposure in the lungs (124 μg min/g) compared with free escitalopram by IN (168 μg min/g) and IV (321 μg min/g) routes. Surprisingly, BorNLC IN instillation increased concentration levels of paroxetine in the brain by five times and accelerated brain drug delivery. Once again, lung exposure was considerably lower with BorNLC (AUCt = 0.433 μg min/g) than that with IV administration (AUCt = 1.01 μg min/g) and non-encapsulated IN formulation (AUCt = 2.82 μg min/g). Direct nose-to-brain delivery was observed for paroxetine IN administration with a direct transport percentage (DTP) of 56.9%. If encapsulated, it increases to 74.2%. These results clearly emphasize that nose-to-brain delivery and lung exposure depend on the formulation and on the characteristics of the drug under investigation. NLCs seem to be an advantageous strategy for nose-to-brain delivery of lipophilic molecules, since they reduce systemic and lung exposure, thereby decreasing adverse effects. For hydrophilic compounds, NLCs are particularly important to decrease lung exposure after IN administration. | pt |
dc.language.iso | eng | pt |
dc.publisher | Frontiers Media | pt |
dc.relation | PD/BDE/150685/2020 | pt |
dc.relation | CENTRO-01-0145-FEDER-030752 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | Brain | pt |
dc.subject | Escitalopram | pt |
dc.subject | Intranasal administration | pt |
dc.subject | Lungs | pt |
dc.subject | Paroxetine | pt |
dc.subject | Pharmacokinetics | pt |
dc.title | Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation | pt |
dc.type | article | - |
degois.publication.firstPage | 751321 | pt |
degois.publication.title | Frontiers in Pharmacology | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3389/fphar.2021.751321 | pt |
degois.publication.volume | 12 | pt |
dc.date.embargo | 2021-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.researchunit | CQC - Coimbra Chemistry Centre | - |
crisitem.author.parentresearchunit | Faculty of Sciences and Technology | - |
crisitem.author.orcid | 0000-0003-3424-548X | - |
crisitem.author.orcid | 0000-0002-3854-6549 | - |
Appears in Collections: | I&D CEFarmacêuticos - Artigos em Revistas Internacionais I&D CQC - Artigos em Revistas Internacionais FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fphar-12-751321.pdf | 1.87 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
9
checked on Jan 29, 2024
WEB OF SCIENCETM
Citations
8
checked on Feb 2, 2024
Page view(s)
207
checked on Oct 2, 2024
Download(s)
188
checked on Oct 2, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License